Paradigm Doses First Subjects in Phase III Knee Osteoarthritis Trial
The trial will compare the effects of PPS subcutaneous injections to placebo on pain and function. In the Phase III clinical trial of injectable pentosan polysulfate sodium (PPS/Zilosul) for the treatment of pain associated with Osteoarthritis Drugs Development Market in the United States, Paradigm Biopharmaceuticals has randomized and dosed the first participants. The trial's first subject was...
0 Comments 0 Shares